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Abstract
Background: To control tuberculosis (TB), it is critical to identify at risk populations. Schizophrenia is recognized as
an important risk factor for TB. However, previous studies have been confounded by comorbidities, and reports of
TB infection outcomes are rare. Therefore, the current nation-wide study aimed to compare the adjusted incidence
and outcome of TB diseases in schizophrenics and the general population.
Method: Using the National Health Insurance Research Database from 1998 to 2009, this retrospective longitudinal
study included 60,409 schizophrenics and general population matched for age, Charlson’s score, and comorbidities.
Diagnosis of TB was based on the international classification of disease, ninth revision and use of anti-TB drugs.
Unfavorable outcome for TB was defined as death, loss to follow-up, or use of anti-TB treatment for more than
9 months.
Results: The adjusted incidence of TB in schizophrenics was significantly higher than in the general population
[hazard ratio, 1.52; 95% confidence interval (CI), 1.29-1.79; p < 0.001; Kaplan-Meier log-rank test, p < 0.001]. Cox
regression revealed age and male gender as risk factors for newly-diagnosed TB. The outcome of TB was
comparable in schizophrenics and the general population [odds ratio (OR), 0.78; 95% CI, 0.55-1.09; p =0.144].
Logistic regression revealed a statistical trend for diabetes mellitus to predict poor outcome in schizophrenics with
TB (OR, 2.30; 95% CI, 0.96-5.74; p = 0.062).
Conclusions: Schizophrenics are at increased risk for TB, and screening may be warranted for those living in areas
with high prevalence of TB.
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Background
Tuberculosis (TB) remains the most prevalent infectious
disease and the major leading cause of death worldwide,
accounting for more than 9 million new cases and 1.4
million deaths [1]. The World Health Organization’s
“Global Plan to Stop TB” aims to eradicate this disease by
2050. An important strategy to control TB infection is to
identify high-risk groups [2]. In addition to well-known
risk factors of TB, such as diabetes mellitus (DM) and
human immunodeficiency virus (HIV), many studies
have demonstrated an increased incidence of TB in
schizophrenics [3-8]. Schizophrenia is a debilitating mental
disease affecting 1% of the general population [9], and it is
often accompanied by physical illnesses [4,5,10] that may
increase susceptibility to TB infection. However, previous
studies have not adjusted for these confounding factors. In
addition, outcomes for schizophrenics with concomitant
TB have rarely been reported, though previous studies
[11,12] reported an increased risk of death due to TB in
patients with mental illness. To adjust for confounding
factors and determine outcomes in schizophrenics requires
studies with larger sample sizes and longer follow-up than
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those previously conducted. Therefore, we conducted a
nation-wide, retrospective longitudinal study that spanned
12 years and included 120,818 people to compare the
adjusted incidence and outcome of TB diseases in schizo-
phrenics and the general population.
Methods
Data source
Taiwan regulations stipulate mandatory registry and treat-
ment of TB via the Directly Observed Treatment Short
Course (DOTS) program, which is monitored by the Center
for Disease Control (CDC, Taiwan). DOTS workers and
public health nurses follow TB cases to monitor compliance
and side effects, and they report directly to the local health
authority. National Health Insurance (NHI) provides
coverage for anti-TB treatment and monitors the cost.
After its implementation by the government under the
principle of mandatory and universal enrollment in 1995,
the NHI program covered 99% of the population of Taiwan.
Computerized claims data for inpatient and outpatient care,
including demographic data, treatment, and diagnosis
by international classification of disease, ninth revision
(ICD-9-CM) [13], were collected and stored in the NHI
Research Database (NHIRD), which is run by the National
Health Research Institute. We retrospectively retrieved
inpatient and outpatient claims data from NHIRD for
the period of January 1998 to December 2009 to compare
the incidence and outcome of newly-diagnosed TB in
schizophrenics and controls.
As the data set used in our study consisted of de-
identified secondary data released to the public for research
purposes, studies of this kind were exempt from full review
by the institutional review board.
Definitions
We performed a nation-wide study of schizophrenics and
matched controls. The schizophrenic cohort comprised all
patients who were admitted with schizophrenia (ICD-9-CM
code 295.x) from January 1, 1998 to December 31, 2009.
Schizophrenia diagnosis was further validated if it was
coded by psychiatrists. The date of admission was consid-
ered the index date. Patients who were diagnosed with TB
(ICD-9-CM codes 010.x to 018.x) before the index date
were excluded.
Control subjects were selected from the Longitudinal
Health Insurance Database dataset, which contains com-
plete data of 1,000,000 randomly sampled beneficiaries
from the original NHIRD. There were no significant
differences in age or gender distribution in this sample of
1,000,000 beneficiaries and the original NHIRD. We
excluded those patients who were diagnosed with schizo-
phrenia and antecedent TB (ICD-9-CM codes 010.x to
018.x). However, there were significant differences in age,
gender, and comorbid disease between schizophrenics and
controls. Thus, we further refined our control cohort cri-
teria by randomly selecting subjects to match schizo-
phrenic patients on age (±2 years), gender, index date,
Charlson’s score [13], chronic pulmonary disease, diabetes,
and rheumatoid disease. To determine the incidence of
TB, subjects were tracked from the index date until
December 31, 2009, death, or diagnosis of TB. The
diagnosis of new TB required the presence of ICD-9-CM
code 010.x-018.x plus prescription of at least two anti-TB
drugs (e.g., isoniazid, ethambutol, rifampin, pyrazinamide)
for two months. Unfavorable outcomes included death,
loss to follow-up, and prolonged treatment, which was
defined as presence of ICD-9-CM code of TB for more
than 9 months. Other comorbid diseases were retrieved
by ICD-9-CM codes from the NHI database inpatient
and outpatient datasets [13].
Statistics analysis
Pearson chi-square tests were used for categorical variables,
while independent t-tests and Mann–Whitney U tests







Age, median 35.4 (26.9-44.9) 35.3 (26.3-45.3) 0.001
Follow-up, days 2,368 (1,449-3,295) 2,296 (1,367-3,222)
Male 33,271 (55.1%) 33,271 (55.1%) >0.99
Charlson's score
0 37,186 (61.6%) 37,186 (61.6%) >0.99
1-2 19,216 (31.8%) 19,216 (31.8%) >0.99
≥3 4,007 (6.6%) 4,007 (6.6%) >0.99
Chronic pulmonary
disease
10,096 (16.7%) 10,096 (16.7%) >0.99
Diabetes 5,179 (8.6%) 5,179 (8.6%) >0.99
Rheumatoid disease 934 (1.5%) 934 (1.5%) >0.99
Peptic ulcer disease 11,548 (19.1%) 10,901 (18.0%) <0.001
Liver disease 7,796 (12.9%) 8,584 (14.2%) <0.001
Hypertension 7,071 (11.7%) 6,903 (11.4%) 0.131
Arrhythmia 6,420 (10.6%) 6,052 (10.0%) <0.001
Dyslipidemia 4,988 (8.3%) 4,843 (8.0%) 0.127
Drug or substance abuse 2,725 (4.5%) 13 (0.02%) <0.001
Chronic kidney disease 1,812 (3.0%) 2,048 (3.4%) <0.001
Cancer 1,282 (2.1%) 1,934 (3.2%) <0.001
Heart failure 819 (1.4%) 861 (1.4%) 0.303
Peripheral vascular
disease
524 (0.9%) 484 (0.8%) 0.206
Myocardial infarction 229 (0.4%) 318 (0.5%) <0.001
Hemiplegia or paraplegia 147 (0.2%) 205 (0.3%) 0.002
AIDS 53 (0.09%) 44 (0.07%) 0.361
Data are median value (interquartile range) for continuous variables and
number of cases (%) for categorical variables. AIDS: acquired
immunodeficiency syndrome.
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were used for parametric and nonparametric continuous
variables, respectively. The incidence of TB diseases
was compared by Poisson distribution method, and the
cumulative incidence of TB diseases was compared by
the Kaplan-Meier method (log-rank test). Risk factors with
p values of < 0.1 in univariate analysis were entered into
the multivariate analysis. Multivariate Cox proportional
hazard regression was performed using backward elimin-
ation to analyze independent risk factors for TB diseases.
A p value of < 0.05 was considered significant.
Results
Baseline characteristics of schizophrenics
A total of 60,409 schizophrenics were included. The median
follow-up period was 2,368 days (range, 1,449-3,295 days).
Table 1 shows the clinical characteristics of this group.
They were predominantly male (33,271, 55.1%), and the
majority (93.4%) did not have any severe comorbidities
(Charlson’s score < 3). The most prevalent underlying
diseases were peptic ulcer diseases (11,549, 19.1%),
chronic pulmonary diseases (10,096, 16.7%), and liver
disease (7,796, 12.9%). A total of 60,409 controls were
matched for gender, Charlson’s score, chronic pulmonary
disease, DM, and rheumatoid disease (All p > 0.99).
Higher incidence and risk factors of newly diagnosed TB
cases in schizophrenics
There were 366 new TB cases among schizophrenics and
241 among controls during the total follow-up period of
771,657 person-years, as shown in Table 2. The crude
hazard ratio (HR) of TB diseases in schizophrenics was
1.48 [95% confidence interval (CI), 1.26-1.74; p < 0.001].
After adjusting for all variables in Table 1, the HR of TB in
schizophrenics was 1.52 (95% CI, 1.29-1.79; p < 0.001)
compared with general population. As shown in Figure 1,
Kaplan-Meier analysis also revealed a higher rate of
Table 2 Incidence and crude and adjusted hazard ratio of newly-diagnosed tuberculosis in schizophrenics and controls
No. Person-years No. with TB Incidence rate (per 105 person-years) Crude HR (95% CI) Adjusted HR1 (95% CI)
Total 120,818 771,657 607 78.7
Schizophrenics 60,409 392,109 366 93.3 1.48* (1.26-1.74) 1.52* (1.29-1.79)
Controls 60,409 379,548 241 63.5 Reference Reference
1Adjusted HR was adjusted for age, sex, gender, Charlson’s score and all comorbidities listed in Table 1. TB: tuberculosis, HR: hazard ratio, CI: confidence interval.
*p < 0.001.
Figure 1 Kaplan-Meier plots of the cumulative incidence of tuberculosis between schizophrenics and control cohort.
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newly-diagnosed TB in schizophrenics (log-rank test,
p < 0.001). Most of the diseases were pulmonary in origin,
occurring in 321 (87.7%) schizophrenics and 206 (85.5%)
controls, as shown in Table 3 (p = 0.50). Compared with
schizophrenics without TB (Table 4), those with TB tended
to have advanced age, male gender, higher Charlson’s score,
DM, myocardial infarction, and hypertension. Cox
regression showed independent risks for newly-diagnosed
TB to be age and male gender, while patients with hyper-
tension were less likely to have new TB diseases.
Comparable outcome of newly-diagnosed TB cases in
schizophrenics and controls
Unfavorable outcomes occurred in 138 (37.7%) of 366
schizophrenics and in 105 (43.6%) of 241 controls with
new TB diseases [crude odds ratio (OR), 0.78; 95% CI,
0.56-1.09; p =0.149]. During anti-TB therapy, 26 (7.1%)
schizophrenics were lost to follow-up, 4 (1.1%) died, and
108 (29.5%) underwent treatment for more than 9 months.
In the control group, 19 (7.9%) were lost to follow-up,
one died (0.4%), and 85 (35.3%) underwent treatment
for more than 9 months (All p > 0.05). After adjusting
for comorbidities, schizophrenics and controls with new
TB diseases had comparable outcomes (OR, 0.78; 95% CI,
0.55-1.09; p = 0.144). Multivariate analysis revealed a
statistical trend for DM to predict poor outcome in
schizophrenics (OR, 2.30; 95% CI, 0.96-5.74; p = 0.062,
Additional file 1: Table S1).
Discussion
Our nationwide study included a total of 60,409 schizo-
phrenics and controls with a median follow-up duration
Table 3 Site of tuberculosis infection among
schizophrenics and controls





Pulmonary 321 (87.7) 206 (85.5) 0.502
Other respiratory 16 (4.4) 16 (6.6) 0.299
Skin, subcutaneous tissue, and
lymph nodes
11 (3.0) 4 (1.7)
0.439
Primary tuberculosis 10 (2.7) 6 (2.5) 0.920
Miliary tuberculosis 3 (0.8) 2 (0.8) >0.99
Meninges and central nervous
system




2 (0.5) 2 (0.8)
0.651
Bones and joints 1 (0.3) 2 (0.8) 0.566
Genitourinary system 0 (0) 2 (0.8) 0.157
Data are number of cases (%).
Table 4 Multivariate Cox regression of risk for newly-diagnosed TB in schizophrenics
Characteristics Univariate Multivariate*
HR 95% CI P value HR 95% CI P value
Age, 1 year 1.05 1.04-1.06 <0.001 1.06 1.05-1.06 <0.001
Male 2.63 2.07-3.35 <0.001 3.13 2.46-3.99 <0.001
Charlson's score 1.18 1.07-1.29 0.001
Diabetes 1.77 1.29-2.43 <0.001
Chronic pulmonary disease 1.26 0.96-1.66 0.097
Rheumatoid disease 1.51 0.71-3.18 0.283
Myocardial infarction 4.70 1.94-11.37 0.001
Heart failure 1.90 0.90-4.01 0.094
Peripheral vascular disease 1.69 0.63-4.52 0.298
Peptic ulcer disease 1.19 0.91-1.55 0.203
Liver disease 1.05 0.76-1.45 0.773
Hemiplegia or paraplegia 1.33 0.19-8.45 0.777
Chronic kidney disease 1.14 0.61-2.13 0.693
Cancer 1.62 0.87-3.05 0.131
Hypertension 1.46 1.08-1.97 0.013 0.68 0.49-0.93 0.017
Dyslipidemia 1.16 0.79-1.71 0.45
Arrhythmia 0.91 0.62-1.33 0.64
Drug or substance abuse 1.44 0.90-2.32 0.13
AIDS 0.05 0.00-2556713 0.74
HR: hazard ratio, CI: confidence interval, AIDS: acquired immunodeficiency syndrome.
Only factors with P value less than 0.1 in the univariate analysis were entered into the multivariate analysis and only factors with P value less than 0.05 in
multivariate analysis was presented.
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of 6 years. After adjusting for underlying diseases, schizo-
phrenics had a higher incidence of newly-diagnosed TB,
but comparable outcomes to the general population.
Independent risk factors for TB in schizophrenics were
age and male gender. A statistical trend was found for DM
as an independent risk factor for unfavorable prognosis in
schizophrenics with TB.
The increased prevalence of TB in schizophrenics
[3-8] may be related to different incidences of physical
comorbidities [5], which could influence the likelihood
of TB diseases. The relative risk of DM and colon cancer
in schizophrenics has been reported as 1.5-2.0 [14] and 2.9
[15], respectively, compared with the general population,
while infection rate of HIV in mentally ill patients was
4-23% compared with 0.3% for the general population in
an area with high prevalence [16]. To our knowledge,
this study has the largest number of schizophrenic subjects
and is the first matched retrospective longitudinal study of
its kind, which enabled adjusting for comorbidities. After
adjustment, the incidence of newly-diagnosed TB was 1.5
times higher in schizophrenics compared to the general
population, lower than previously reported [3-8]. The
reason for the higher risk of TB in schizophrenics is
unknown. Development of TB has been associated with
several biological and social factors [1,17]. By adjusting
biological factors, our study may indicate behavior and
socioeconomic factors play an important role [17,18].
First, overcrowding and close contact is an established
risk factor for TB [19]. Josoph et al. recently reported an
outbreak within an assisted living facility for adults with
mental illness [20], concluding that elevated risk for TB
disease among this population was due to sustained
transmission in crowded settings. Second, mentally ill
patients have higher levels of substance abuse, such as
smoking or alcohol use [21], which has been associated
with active TB diseases [1]. Third, the low socioeconomic
status of this vulnerable population [22,23] may predispose
them to TB diseases [24]. Fourth, poor communication
skills in this group may prevent or delay diagnosis and
management of physical diseases [25]. Unfortunately, the
anonymous and hospital-based nature of the NHI database
precluded collection of data related to socioeconomic
status and whether subjects lived in community-based fa-
cilities. Further studies are needed to evaluate the influence
of these behavioral and socioeconomic factors on incidence
of newly-diagnosed TB cases in schizophrenics.
The relative risk of death due to TB in patients with
mental illness has been decreasing from 7.0 in the 1930s
to 5.5 in the 1970s [11,12]. This has been attributed to
improvements in treatment [3]. In our study, the rates of
unfavorable outcomes for TB (mortality, loss to follow-up,
and prolonged treatment) were comparable between
schizophrenics and the general population after adjusting
for comorbidities. This may be explained by coverage of
99% of the population by Taiwan NHI, as well as policies
by the Taiwan CDC for enhancing diagnosis, follow-up,
and treatment [26,27].
Conclusions
In conclusion, schizophrenics had a higher incidence of
newly-diagnosed TB than the general population. Fortu-
nately, with advances in treatment and support from the
national health care system, outcomes from TB were com-
parable in schizophrenics and the general population.
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